DEA Weighs First-Ever LSD Import License for CalCog
Published Date: 6/8/2026
Notice
Summary
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Application to Import Schedule I Drugs
On April 30, 2026, CalCog Inc. (Bastrop, Texas) applied to be registered to import four Schedule I controlled substances: lysergic acid diethylamide (LSD, code 7315), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT, code 7431), dimethyltryptamine (DMT, code 7435), and psilocyn (code 7438). The company says it plans to import these substances only as dosage units for clinical trials; the registration would not authorize other activities or importation of finished dosage forms for commercial sale.
Comment and Hearing Deadline for Stakeholders
Registered bulk manufacturers of the listed drug classes and other applicants may submit electronic comments or objections through Regulations.gov, or file written requests for a hearing, on or before July 8, 2026. Comments submitted electronically will receive a Comment Tracking Number; written hearing requests must be sent to the DEA Hearing Clerk and Administrator at the Springfield, Virginia addresses listed in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2026-11413, Agency Information Collection Activities; Submission to the Office of Management and Budget; Northeast Region Hunter Participation Surveys
The U.S. Fish and Wildlife Service wants to keep collecting info from hunters in the Northeast to better understand hunting habits. This renewal won’t cost hunters money but helps the agency plan wildlife management smarter. If you have thoughts, you’ve got until July 8, 2026, to share them!
Next: 2026-11417, Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just added Amir Hossein Rad from Iran to its sanctions blacklist, blocking all his U.S.-related property and banning Americans from doing business with him. At the same time, some folks got their names removed from the list, meaning their assets are now unblocked. These changes took effect on June 2, 2026, so watch out for new rules and restrictions that could impact money and deals fast!